LAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN),

a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October:

• 
  Chardan’s 5
  
  
  ^th
  
  
  Annual Genetic Medicines Conference
  
  . Michael H. Tardugno, Celsion’s chairman, president and chief executive officer, and Khursheed Anwer, Ph.D., Celsion’s chief scientific officer, will participate in a presentation and fireside chat on October 5, 2021 at 4:30 p.m. ET. Management will be available for 1×1 meetings on October 4 and 5, and investors should contact their Chardan representative to arrange a virtual meeting.
• 
  LD Micro Main Event
  
  . Jeffrey W. Church, chief financial officer, will present virtually at 9:00 a.m. ET on October 12, 2021.
• 
  Alliance Global Partners’ Virtual Healthcare Conference
  
  . Mr. Tardugno will participate in an oncology focused panel discussion moderated by James Molloy on October 13, 2021 at 9:00 a.m. ET.
  

Live and archived webcasts of these presentations will be available

here

.

About Celsion Corporation

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox

^®

, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit


www.celsion.com


.

CONTACTS:

Celsion Corporation


Jeffrey W. Church

Executive Vice President and CFO

609-482-2455



[email protected]

LHA Investor Relations


Kim Sutton Golodetz

212-838-3777



[email protected]

# # #